{"data":{"type":"company_profile","id":149371,"entity_id":"wefunder:company:149371","attributes":{"canonical_url":"https://wefunder.com/phormed","generated_at":"2026-06-06T14:01:10Z","updated_at":"2026-06-06T05:02:11Z","entity_ids":{"company":"wefunder:company:149371","slug":"wefunder:company_slug:phormed"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-06T14:01:10Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-06T05:02:11Z","as_of":"2026-06-06T14:01:10Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-06T05:02:11Z","as_of":"2026-06-06T14:01:10Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-06T14:01:10Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-06T14:01:10Z","confidence":"medium"}}},"company":{"id":149371,"entity_id":"wefunder:company:149371","slug":"phormed","name":"PhorMed","tagline":"Join Us in the Fight to Cure Cancer! Pre-Public Limited Time Offer *10% Bonus Discount*\r\n\r\n","story":"The company anticipates a clear path toward an open and ever-growing marketplace. Our planned GO-PUBLIC transaction offers our investors an exit strategyWe save lives by treating life-threatening diseases, repairing damaged cells, killing cancer cells to destroy cancer at its coreOur *platform drug reverses disease utilizing cell repair therapy to target damaged and mutated cells, having the ability to fix various cell types and kill cancer cells. Additionally, our drug boosts the immune system’s ability to fight cancer, an activity called immunotherapy. The drug is administered through intravenous infusions (I.V. drip).*Platform is defined as one drug applied across many applications.Many common life-threatening diseases have few to no treatment options or require dangerous treatments with long-lasting side effectsMany patients are often faced with the harsh reality of either no viable treatment options or, in cases like cancer, having to endure harmful and painful treatments with severe, long-lasting, and possible organ-damaging side effects. These harsh treatments can increase the already high chance of relapse. In some cases, severe side effects show up years after treatment.Our platform drug shows unparalleled promise in curing cancer and various other deadly diseases, giving patients the opportunity to reclaim their health and live fuller livesWe are currently in clinical trials, advancing the development of our platform drug, RP-323. This treatment targets life-threatening diseases, including Acute Myeloid Leukemia (AML) and Hodgkin’s Lymphoma (cancer) in patients with relapsed/refractory disease, meaning their cancer resisted treatment or came back after first getting better, as well as Parkinson’s disease (brain disorder) and Acute Respiratory Distress Syndrome (ARDS/Lung disorder).Our technology is a targeted therapy that can repair a variety of damaged and mutated cells while killing cancer cells to directly attack cancer at its root.(Watch the Video Below!)While we actively work on our go-public transaction, we continue to evaluate partnership opportunities for ongoing R\u0026amp;D and future distribution, allocating funds in the most efficient manner to achieve our primary goal: clinical success and saving lives.Our cell repair therapy:• Helped 83% of our AML patients beat cancer• Delivers significant tumor reduction in Hodgkin's Lymphoma• Reduces lung inflammation, a key driver of ARDS, helping patients breathe again.• Reduces brain inflammation, addressing a major factor in Parkinson’s disease progression• Earned FDA has Fast-Tracked Phase 1 and Phase 2 for both our cancer studies• Increases White Blood Cells (WBC) \u0026amp; Neutrophils (NEUT)*(WBC \u0026amp; NEUT are part of the cancer-fighting immune system - see image below)Our treatments set a new standard by prioritizing safety and effectiveness, tackling diseases at their root cause rather than merely alleviating symptomsWhile current treatment options for some diseases can cause devastating side effects and possibly damage internal organs and healthy cells, particularly with cancer drugs, other disease states like Parkinson's and ARDS are limited to treatments only relieving symptoms.Our drug changes that. It targets the underlying cause of these diseases, protecting organs and healthy cells from being damaged. We aim to offer safe and targeted treatments in places where they are not currently available.Our drug has been proven to be safe in early studiesThe Phase I Study has been completed, establishing the safety validity of our drug. We are now in Phase II in 3 of our clinical studies.These deadly diseases are widespread, with many untapped markets clear of competitionCurrently, the only medicines available for indications (medical conditions) like ARDS and Parkinson’s are symptom-treating drugs. We would control large sectors of the market void of completion with our targeted disease-focused treatments.Qualifications:Phase 3: 0 clinical trials (all companies have zero trials in Phase 3).Phase 2: 2 or 3 clinical trials (PhorMed has the advantage with 3 clinical trials at this stage compared to others with only 2).Phase 1 \u0026amp; Pre-Clinical: All have additional clinical trials and studies in development.With projected market values ranging between $290M-$1.2B, PhorMed has remarkable growth potential at just $53 million. Invest now and grow with the company.","location":"Los Angeles, CA","website":"https://phormed.com","total_amount_raised":204025,"total_investors":228,"is_funded":true,"is_active":true,"quality_score":3,"related_urls":["https://wefunder.com/phormed","https://phormed.com"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/149371/xxl_blob.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/149371/large_blob.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/149371/standard_blob.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/149371/standard_blob.jpg"},"links":{"company_url":"https://phormed.com","linkedin_url":"https://linkedin.com/company/phormed","facebook_url":"https://facebook.com/invest.phormed","instagram_url":"https://instagram.com/invest.phormed","youtube_url":"https://youtube.com/invest.phormed"},"highlights":[{"id":62736,"name":"notable_angel","url":"notableangel","presentable_name":"Notable Angel","description":"Raised $25k or more from a notable angel investor","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"In a clinical study, we helped 83% of patients beat cancer"},{"index":2,"claim_id":"claim-fact-2","value":"Our drug repairs damaged cells and kills cancer"},{"index":3,"claim_id":"claim-fact-3","value":"On a mission to bring new hope and a brighter future to patients battling life-threatening diseases"},{"index":4,"claim_id":"claim-fact-4","value":"$3.5 million raised from \u0026gt;4,100 investors: Crowdfunding and Angel investors"},{"index":5,"claim_id":"claim-fact-5","value":"Undervalued position, potential to buy low/sell high. PhorMed = $53M; Similar Companies = $290M-1.2B"},{"index":6,"claim_id":"claim-fact-6","value":"FDA allowing “FAST-TRACKING” clinical studies = huge time \u0026amp; cost savings"},{"index":7,"claim_id":"claim-fact-7","value":"Our team has 533 peer-reviewed publications"},{"index":8,"claim_id":"claim-fact-8","value":"Company is ready to start three phase 2 studies"}],"team":[{"id":4076005,"entity_id":"wefunder:company_role:4076005","user_entity_id":"wefunder:user:4195708","role":"founder","name":"Ben Chang","title":"CEO/Director","bio":"Mr. Chang has over 30 years of pharmaceutical and executive-level experience. He also has experience in international banking, venture capital, M\u0026amp;A, finance, go-public transactions, and organizational design and operations. He holds 2 patents.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/4076005/square_blob.jpg?1773077182","profile_url":"https://wefunder.com/ben.chang.1","related_urls":["https://wefunder.com/ben.chang.1"]},{"id":4100763,"entity_id":"wefunder:company_role:4100763","role":"employee","name":"Prof. Richard L. Chang","title":"Inventor/CSO","bio":"Dr. Chang has authored 122 peer-reviewed journal publications; has filed 9 patents for the treatment of cancer, inflammation, hematology, and neurological disorders; and has presented over 150 scientific abstracts.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/4100763/square_blob.jpg?1773077182","related_urls":[]},{"id":4100764,"entity_id":"wefunder:company_role:4100764","role":"employee","name":"Carole A. Salvador, Psy.D","title":"Secretary/Treasurer/HR Director","bio":"Dr. Salvador is the founder of Affiliates in Psychology and Education with over 34 years of experience. She was a principal at Cogent Resources and worked in Biochemistry research at Cornell Medical School and Pharmacology research at Burroughs Welcome.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/4100764/square_blob.jpg?1773077182","related_urls":[]},{"id":4100765,"entity_id":"wefunder:company_role:4100765","role":"employee","name":"Sean M. O'Connell, Ph.D","title":"CCO","bio":"Mr. O’Connell has over 30 years of experience as a Director, Medical Director, COO, CMO, Medical Director, Clinical Research Manager, and VP \u0026amp; SVP of Medical Affairs. He has 65 peer-reviewed publications and 38 abstracts.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/4100765/square_blob.jpg?1773077182","related_urls":[]},{"id":5158800,"entity_id":"wefunder:company_role:5158800","user_entity_id":"wefunder:user:4458492","role":"employee","name":"Joseph Huffman","title":"Finance Director","bio":"Joseph has 32 years of experience in finance and accounting, having worked as a VP in commercial lending and managing partner at Huffman \u0026amp; Huffman LLC CPAs since 1998. A CPA for 28 years, he's also served as a biotech Finance Director for over 13 years.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5158800/square_blob.jpg?1773077182","profile_url":"https://wefunder.com/joseph.huffman","related_urls":["https://wefunder.com/joseph.huffman"]},{"id":5156051,"entity_id":"wefunder:company_role:5156051","role":"employee","name":"Julian Cepeda","title":"Head of Operations","bio":"Julian has a proven track record of executing and scaling digital paid media campaigns for brands like Marriott Hotels and Yuzu Group in the UK. He specializes in enhancing brand visibility and optimizing conversion rates. He holds a Masters in Marketing.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5156051/square_blob.jpg?1773077182","related_urls":[]},{"id":5092056,"entity_id":"wefunder:company_role:5092056","user_entity_id":"wefunder:user:4410962","role":"employee","name":"Xiaoxin Luke Chen","title":"Advisory Board","bio":"Dr. Chen is the Surgical Research Director at Cooper University Health Care. With over 30 years of experience, 5 book contributions, and 127 peer-reviewed publications, he has made significant contributions to cancer research.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5092056/square_blob.jpg?1773077182","profile_url":"https://wefunder.com/xiaoxin.luke.chen","related_urls":["https://wefunder.com/xiaoxin.luke.chen"]},{"id":4162078,"entity_id":"wefunder:company_role:4162078","role":"employee","name":"Professor Renping Zhou","title":"Advisory Board","bio":"Mr. Zhou is the current Chairperson and Professor in the Department of Chemical Biology at Rutgers University in New Jersey. He has 36 years of experience in cancer research, has been awarded multiple grants, and has 162 peer-reviewed publications.","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png?1773077182","related_urls":[]},{"id":4162082,"entity_id":"wefunder:company_role:4162082","role":"employee","name":"Professor Xi Zheng","title":"Advisory Board","bio":"Mr. Zheng currently holds the positions of Director, Research Professor, Unilever Chair and Associate member at Rutgers Cancer Institute of New Jersey. He has 102 peer-reviewed publications and 37 years of experience in cell biology, and cancer research.","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png?1773077182","related_urls":[]},{"id":4162086,"entity_id":"wefunder:company_role:4162086","role":"employee","name":"Professor Harold H. Lee","title":"Advisory Board","bio":"Professor Lee has more than 20 peer-reviewed scientific papers in developmental biology and biotechnology, 4 patents in biotechnology, and 4 novels.","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png?1773077182","related_urls":[]}],"featured_investors":[{"id":7407,"entity_id":"wefunder:company_investor_profile:7407","investor_profile_id":3693660,"investor_profile_entity_id":"wefunder:investor_profile:3693660","subject_entity_id":"wefunder:user:4207745","name":"Edward Pan","role_title":"","bio":"Founder of Chiropractic Care Center, his expertise includes chiropractic care, physiotherapies and cold laser therapies.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6NTgxNjIsInB1ciI6ImJsb2JfaWQifX0=--4ebe2ba26a23da9d9f43d18f73db1c12eb51bba5/filename","profile_url":"https://wefunder.com/edward.pan","endorsement_quote":"I invested in PhorMed because, being in the medical field myself, I believe the technology to be exciting and groundbreaking. The drug being developed has great potential to help save lives while increasing the quality of life to many who do not currently have treatment options. I also like that the company’s technology was fast tracked by the FDA. Seems the company has provided ample clinical support for the FDA to help move trials forward in a more rapid pace which is also a huge overall cost savings to the company","endorsement_name":"","investment_total":20000,"investment_info":"Invested $10,000 this round \u0026 $10,000 previously","is_lead_investor":true,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/edward.pan"]},{"id":8741,"entity_id":"wefunder:company_investor_profile:8741","investor_profile_id":3821857,"investor_profile_entity_id":"wefunder:investor_profile:3821857","subject_entity_id":"wefunder:notable_investor:12208","name":"James Charleston","role_title":"","bio":"Currently serving as the Director of Global Sales Engineering at CloudLinux/TuxCare; Experience also includes entrepreneurship as founder, president, and CEO of URTECHS, LLC.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTAwMDk3LCJwdXIiOiJibG9iX2lkIn19--f113439898dccdb7067284dea0fb05421b33cd06/filename","profile_url":"https://wefunder.com/james.charleston.1","endorsement_quote":"Investing in Hope: My Journey with PhorMed” “My investment journey is personal, driven not by wealth but by a commitment to meaningful innovation. PhorMed's groundbreaking approach, which harnesses the body's own mechanisms at the DNA/RNA level for healing, immediately resonated with me. This philosophy of aiding the body to heal itself mirrors my own beliefs, shaped by my family's battles with various cancers and our collective hope for revolutionary treatments. Our daughter's dedication to cancer research, aiming for a Ph.D., further cements our family's commitment to supporting innovative solutions in healthcare. PhorMed's focus on personalized, body-centric therapies offers a new direction in the fight against cancer, promising a future where treatments are as natural as the body's instinct to heal. Choosing to invest in PhorMed was more than a financial decision; it was a pledge to a future where advanced, individualized treatments become a reality, offering hope where it's most needed.","endorsement_name":"","investment_total":1966,"investment_info":"Invested $1,250 this round \u0026 $716 previously","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/james.charleston.1"]}],"investor_memos":[],"tab_counts":{"posts":0,"ask_questions":18,"featured_investors":2,"faq_entries":5},"active_fundraises":[{"id":105392,"entity_id":"wefunder:fundraise:105392","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":250,"max_purchase":9,"funding_target":5000000.0,"minimum_target":"50000.0","maximum_target":"5000000.0"},{"id":105391,"entity_id":"wefunder:fundraise:105391","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"custom","security_type":"custom","currency":"USD","testing_the_waters":false,"min_purchase":250,"max_purchase":9,"funding_target":5000000.0,"minimum_target":"50000.0","maximum_target":"5000000.0","funding_started_at":"2023-12-15T00:33:47Z","funding_closed_at":"2026-05-01T03:59:59Z","auto_close_at":"2026-05-01T03:59:59Z"}],"latest_fundraise":{"id":105392,"entity_id":"wefunder:fundraise:105392","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":null,"nb":null,"txt":null}},"recent_posts":[],"q_and_a":[{"id":280773,"entity_id":"wefunder:comment:280773","question":"Hi Ben , I have already invested in your company through start engine. 2years back. At that time also your valuation was the same as of today. Why?? Why are you raising funds at same valuation? It is nothing but dilution of shares through unfair practices. Are you people at all doing some serious business or planning to just raise funds and close the business after the fund raising?? answer...","author_name":"Arghya Chatterjee","votes":4,"created_at":"2024-04-06T05:58:28Z","canonical_url":"https://wefunder.com/phormed#question-280773","answers":[{"id":289718,"entity_id":"wefunder:comment:289718","answer":"Arghya, apologies for the delayed response. Since your purchase the stock prices remain the same so no losses to your investment. The company is hitting milestones and stock price increases happen shortly after. Stand-by for those announcements.","author_name":"Ben Chang","votes":0,"created_at":"2024-08-07T07:38:03Z"}]},{"id":285159,"entity_id":"wefunder:comment:285159","question":"How many shares will my $250 investment secure?","author_name":"Larry R Miffleton","votes":3,"created_at":"2024-06-13T16:46:36Z","canonical_url":"https://wefunder.com/phormed#question-285159","answers":[{"id":285322,"entity_id":"wefunder:comment:285322","answer":"Larry, thank you for your question. Currently, we are running an early bird special, discounting the share price by 10% from $1.00 to $0.90. A $250 investment will get you 277 shares.","author_name":"Ben Chang","votes":1,"created_at":"2024-06-17T20:42:30Z"}]},{"id":289941,"entity_id":"wefunder:comment:289941","question":"Mr . Ben. I know that you are reading my questions but no courage to answer.Update your recent clinical trial progress. And what is the time line you have set to launch your first product in the market and investor exit plan too.","author_name":"Arghya Chatterjee","votes":2,"created_at":"2024-08-09T06:27:30Z","canonical_url":"https://wefunder.com/phormed#question-289941","answers":[]},{"id":275150,"entity_id":"wefunder:comment:275150","question":"With the Common Stock will we receive annually dividends?","author_name":"Adan Farrah","votes":2,"created_at":"2024-01-31T16:17:30Z","canonical_url":"https://wefunder.com/phormed#question-275150","answers":[{"id":275935,"entity_id":"wefunder:comment:275935","answer":"Adan, thanks for your question. This offering does not include dividends..","author_name":"Ben Chang","votes":1,"created_at":"2024-02-10T02:35:47Z"}]},{"id":332083,"entity_id":"wefunder:comment:332083","question":"No major improvement seen in this company since last 5 years. Only raising funds. Does it have any business at all or planning to go away with money. Seriously I have doubt on their business and compliance. They are just changing the fund raising platforms. No major business or company valuation increase. Mr ben do you have any guts to answer?","author_name":"Arghya Chatterjee","votes":1,"created_at":"2026-04-26T13:20:07Z","canonical_url":"https://wefunder.com/phormed#question-332083","answers":[]},{"id":325273,"entity_id":"wefunder:comment:325273","question":"Why is there no new news on your website and search engines since 2024, and your email address doesn't work as listed on your site?","author_name":"Larry Yonish","votes":1,"created_at":"2026-02-13T18:09:19Z","canonical_url":"https://wefunder.com/phormed#question-325273","answers":[]},{"id":322748,"entity_id":"wefunder:comment:322748","question":"With respect to your target of Hodgkin’s Lymphoma, my understanding is that 5-year progression free survival with existing treatments, especially N+AVD (with Nivolumab as the immunotherapy drug) is already around 90% with most patients making full recovery without the need for radiation. How would your compound improve on the outcome for patients from existing therapies?","author_name":"Bernardo Piereck","votes":1,"created_at":"2026-01-09T23:05:04Z","canonical_url":"https://wefunder.com/phormed#question-322748","answers":[{"id":327322,"entity_id":"wefunder:comment:327322","answer":"Bernardo, thank you for your question! For Hodgkin's Lymphoma, our target population is relapsed/refractory patients, meaning patients whose cancer either resisted treatment or returned after first getting better. You can find this info in our \"Solution\" section of our pitch","author_name":"Ben Chang","votes":1,"created_at":"2026-03-10T16:33:43Z"}]},{"id":298443,"entity_id":"wefunder:comment:298443","question":"Thanks for clarifying. I searched for your phase 2 studies in FDAs database but could not locate them. Can you please provide a link? My querry: https://clinicaltrials.gov/search?cond=Aml\u0026amp;aggFilters=phase:2\u0026amp;sort=StudyFirstPostDate","author_name":"Mads Georgsen","votes":1,"created_at":"2024-12-19T20:46:42Z","canonical_url":"https://wefunder.com/phormed#question-298443","answers":[]},{"id":282529,"entity_id":"wefunder:comment:282529","question":"Mr Ben any courage to give any answer???","author_name":"Arghya Chatterjee","votes":1,"created_at":"2024-04-28T17:34:32Z","canonical_url":"https://wefunder.com/phormed#question-282529","answers":[{"id":289848,"entity_id":"wefunder:comment:289848","answer":"Arghya, please see my response above.","author_name":"Ben Chang","votes":0,"created_at":"2024-08-08T09:09:41Z"}]},{"id":334857,"entity_id":"wefunder:comment:334857","question":"I thinks it's time for an update. Please share the latest news, either good or bad.","author_name":"Rijkele Woudwijk Trust","votes":0,"created_at":"2026-06-03T03:55:02Z","canonical_url":"https://wefunder.com/phormed#question-334857","answers":[]},{"id":328174,"entity_id":"wefunder:comment:328174","question":"What is the exit plan (acquisition, IPO, merger, etc.) in which investors will be able to see a ROI?","author_name":"bugg logg","votes":0,"created_at":"2026-03-19T00:55:36Z","canonical_url":"https://wefunder.com/phormed#question-328174","answers":[]},{"id":316856,"entity_id":"wefunder:comment:316856","question":"Hi, considring your cooperation with overseas labs, are the recent policies on imported drugs going to affect your business plan and how much?","author_name":"Mirko Turrina","votes":0,"created_at":"2025-10-13T07:15:42Z","canonical_url":"https://wefunder.com/phormed#question-316856","answers":[{"id":317302,"entity_id":"wefunder:comment:317302","answer":"Hi Mirko, thanks for your question! It does not affect us at this point. We have enough inventory on hand for the next couple of years.","author_name":"Ben Chang","votes":0,"created_at":"2025-10-17T15:04:24Z"}]},{"id":309769,"entity_id":"wefunder:comment:309769","question":"What is the current revenue?","author_name":"Y S","votes":0,"created_at":"2025-06-16T18:47:51Z","canonical_url":"https://wefunder.com/phormed#question-309769","answers":[{"id":309946,"entity_id":"wefunder:comment:309946","answer":"Hi Yaacov, thanks for your question! We are currently pre-revenue and in drug development/clinical studies.","author_name":"Ben Chang","votes":0,"created_at":"2025-06-19T13:28:28Z"}]},{"id":297638,"entity_id":"wefunder:comment:297638","question":"Can you elborate on the study design for your phase 2 studies? (How many patients, how long study time etc…)","author_name":"Mads Georgsen","votes":0,"created_at":"2024-12-07T21:34:23Z","canonical_url":"https://wefunder.com/phormed#question-297638","answers":[{"id":298346,"entity_id":"wefunder:comment:298346","answer":"Mads, thank you for your question! The study design is an open-label Phase 2 trial with 35 patients, requiring 20% efficiency (Fast-tracked status). Each treatment cycle lasts approximately 2-3 months, and the overall trial duration is expected to be around 24-30 months. Let me know if you have further questions or need additional details!","author_name":"Ben Chang","votes":1,"created_at":"2024-12-18T19:50:51Z"}]},{"id":291817,"entity_id":"wefunder:comment:291817","question":"Can you speak more directly about your IP? I couldn't find it on your website (also your financials are nearly 3 years out of date). They photo caption in the overview says you received patents in 2019 and 2020. Are those owned by the company or licensed from Dr. Chang (and under what terms)? Should we assume that is the total of the IP? Are there other patents? If so, what? Is the viability of a final product predicated on any other IP/patents that you do not directly control and would need to license?","author_name":"Lance Longwell","votes":0,"created_at":"2024-09-06T18:13:01Z","canonical_url":"https://wefunder.com/phormed#question-291817","answers":[{"id":291934,"entity_id":"wefunder:comment:291934","answer":"Lance, thanks for your question regarding our IP. All of our indications within our pipeline are on the list of our IP and are all patent-protected. All are assigned, not licensed, from Prof. Richard L. Chang, so we have full ownership and rights and are not reliant on any other third parties. If and when we have IP expansion, we will add them to our pipeline, and updates and press releases will be made.","author_name":"Ben Chang","votes":0,"created_at":"2024-09-09T09:20:37Z"}]},{"id":291813,"entity_id":"wefunder:comment:291813","question":"Another question, your manufacturing partner is WuXi. While the Biosecure Act did not pass earlier in the summer, the long-term viability as a partner is questionable (WuXi has withdrawn from BIO, import restrictions still in place, etc.). What is your operational plan to de-risk your supply chain exposure and provide an adequate product supply for future trials?","author_name":"Lance Longwell","votes":0,"created_at":"2024-09-06T17:45:00Z","canonical_url":"https://wefunder.com/phormed#question-291813","answers":[{"id":291933,"entity_id":"wefunder:comment:291933","answer":"Lance, thanks again for your question. We do not collect genomic data nor do we share any data with WuXi or any other third parties, wherever they may be located. However, once we reach the market with any indication, our plan is to manufacture in-house, resolving all CDMO relationships.","author_name":"Ben Chang","votes":0,"created_at":"2024-09-09T09:16:52Z"}]},{"id":291812,"entity_id":"wefunder:comment:291812","question":"Just to clarify, Phormed has a single asset candidate (RP-323) across the 4 indications?","author_name":"Lance Longwell","votes":0,"created_at":"2024-09-06T17:41:02Z","canonical_url":"https://wefunder.com/phormed#question-291812","answers":[{"id":291932,"entity_id":"wefunder:comment:291932","answer":"Lance, thank you for your question. Correct, PhorMed’s drug is a single small molecule with the ability to follow specific pathways throughout the body, having the ability to repair certain cells. You can go here phormed.com/science/how-it-works to learn more.","author_name":"Ben Chang","votes":0,"created_at":"2024-09-09T09:13:41Z"}]},{"id":289159,"entity_id":"wefunder:comment:289159","question":"When is this funding round closing?","author_name":"Douglas Walton","votes":0,"created_at":"2024-07-30T15:52:41Z","canonical_url":"https://wefunder.com/phormed#question-289159","answers":[{"id":289532,"entity_id":"wefunder:comment:289532","answer":"Douglas, thank you for your question. We expect to close this round in mid-April 2025.","author_name":"Ben Chang","votes":0,"created_at":"2024-08-05T13:11:55Z"}]}],"faq":[{"question":"With the Common Stock will we receive annually dividends?","answer":"Adan, thanks for your question. This offering does not include dividends.."},{"question":"Hi Ben , I have already invested in your company through start engine. 2years back. At that time also your valuation was the same as of today. Why?? Why are you raising funds at same valuation? It is nothing but dilution of shares through unfair practices. Are you people at al...","answer":"Arghya, apologies for the delayed response. Since your purchase the stock prices remain the same so no losses to your investment. The company is hitting milestones and stock price increases happen shortly after. Stand-by for those announcements."},{"question":"Mr Ben any courage to give any answer???","answer":"Arghya, please see my response above."},{"question":"How many shares will my $250 investment secure?","answer":"Larry, thank you for your question. Currently, we are running an early bird special, discounting the share price by 10% from $1.00 to $0.90. A $250 investment will get you 277 shares."},{"question":"When is this funding round closing?","answer":"Douglas, thank you for your question. We expect to close this round in mid-April 2025."}]}}}